Factors Affecting Bone Mineral Density in Hemodialysis Patients
Abstract
Objective: Disorders of mineral metabolism and bone density are common complications in chronic kidney disease and are an important cause of morbidity. Recently used definition is chronic kidney disease-mineral and bone disorder (CKD-MBD). The aim of our study was to evaluate the correlation between bone mineral density and influencing factors in patients with end-stage renal failure undergoing hemodialysis.
Material and Methods: In our study, cases were evaluated by being divided into 3 groups depending on bone mineral density (BMD). Our study included 124 cases and was designed as a cross-sectional observational study. The demographic data of the cases were recorded separately for each case. Routine biochemical analyses were studied.
Results: The median vit D value of the patients with osteoporosis participated in the study was 14.44 mg/dl in the osteopenic group and the median value of the patients without osteoporosis was 20.14 mg/dl. The lowest and highest vit D values of the patients with osteoporosis were 3 mg/dl and 34.77 mg/dl, respectively. There was a statistically significant difference between all 3 groups for the age variable (p=0.002). There was a statistically significant difference between all 3 groups for the BMI variable (p=0.011). For 3 groups divided according to BMD measurements, statistically significant results were found in the PTH, Ferritin, Hgb, CRP, ALP, Albumin, e-GFR, hip and lumbar BMD values, respectively (p<0.001, p=0.001, p=0.004, p=0.001, p=0.003,p=0.005, p=0.001, p<0.001, p<0.001).
Conclusion: In conclusion, our study revealed that the most
important risk factor associated with osteoporosis in patients undergoing
hemodialysis was PTH elevation and low vitamin D levels. For this purpose, BMD
measurements and biochemical parameters of CKD patients undergoing hemodialysis
should be studied in appropriate periods by adhering to the guidelines. Vit D
replacement should not be neglected in order to avoid osteoporosis and to treat
the detected cases.
Keywords
References
- 1.Block GA, Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. In: Olgaard K (ed). Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD. chapter 4 National Kidney Foundation: New York, 2006, 77–92.
- 2.Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005;63(2): 138–45.
- 3. Quarles LD, Berkoben M, Management of secondary hyperparathyroidism in dialysis patients Literature review current through: Nov 2018. | This topic last updated: Nov 06, 2018.
- 4. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92(1):26-36.
- 5. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis.Osteoporos Int.2014;25(10):2359-81.
- 6.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843: 1–1297. Posa F, Di Benedetto A, Colaianni G, Cavalcanti-Adam EA, Brunetti G, Porro C et al. Vitamin D Effects on Osteoblastic Differentiation of Mesenchymal Stem Cells from Dental Tissues. Stem Cells Int. 2016;2016:9150819. Epub 2016 Nov 13.
- 7. Posa F, Di Benedetto A, Colaianni G, Cavalcanti-Adam EA, Brunetti G, Porro C et al. Vitamin D Effects on Osteoblastic Differentiation of Mesenchymal Stem Cells from Dental Tissues. Stem Cells Int. 2016;2016:9150819. Epub 2016 Nov 13.
- 8.Tominaga Y, Matsuoka S, Sato T, Uno N, Goto N, Katayama A, et al. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy. Ther Apher Dial 2007; 11 (issue 4): 266-73
- 9. Defechereux T, Meurisse M. Renal hyperparathyroidism: Current therapeutic approach and future directions. Operative Tecniques in Otolaryngology 2009; 20(1) 71-8.
- 10.Aksu A, Zinnuroglu M, Karaoğlan B, Akın S, Kutsal YG, Atalay F, Dincer G. Osteoporosis, Education Status and Knowledge Level Research Results Osteoporosis’ s World 2005; 11(1) 36-40.